Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07011979

SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease

SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
10 Years
Healthy volunteers

Summary

The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence. The main question it aims to answer is: What are the risk factors for developing Inflammatory Bowel Disease? Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD. Participants will * undergo assessments of general demographic and clinical characteristics. * be monitored for symptoms using questionnaires administered at regular intervals. * have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.

Detailed description

Recruitment announcements for participants who are first-degree relatives with patients of IBD will be posted on the bulletin board of the patient community, the outpatient bulletin board, and in the consultation room. For patients with confirmed Anti-Saccharomyces cerevisiae antibody (ASCA) positivity or those diagnosed with autoimmune diseases, recruitment will be conducted from among outpatients who meet the criteria. Detailed explanations about the study will be provided, and consent to participate will be obtained prior to recruitment. Blood and stools will be used for genomic and proteomic, metabolomic analysis. 16s rRNA gene sequencing and whole genome shotgun sequencing will be done for microbiome analysis. Biopsy specimen will be used for proteomic analysis. Adverse events related with blood sampling will be monitored in outpatient clinic.

Conditions

Timeline

Start date
2022-01-07
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2025-06-10
Last updated
2025-06-10

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT07011979. Inclusion in this directory is not an endorsement.